Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com

CANNANNEW REPORT

DUBLIN–(BUSINESS WIRE)–The “Dyskinesia (Central Nervous System) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Dyskinesia – Drugs In Development, 2021, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication. Report Highlights Dyskinesia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 15, 8, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively. The Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System). The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide…

Excerpt only …
READ MORE BELOW
Source : Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.